Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics.

Cancer metastasis reviews - 10 Sept 2026

Li Quan, Hu Jiancheng

Abstract excerpt

Langerhans cell histiocytosis (LCH) is a nonhereditary myeloid neoplasm driven by somatic alterations in the mitogen-activated protein kinase (MAPK) signaling pathway, most commonly involving BRAF and MAP2K1 (MEK1). Oncogenic BRAF alterations activate MAPK signaling through diverse structural mechanisms. The prominent BRAF(V600E) mutation traps BRAF in a constitutively active status by forming the K507-E600 salt...

Read the complete abstract on PubMed

Topics

Humans
Histiocytosis, Langerhans-Cell
Molecular Targeted Therapy
Animals
Proto-Oncogene Proteins B-raf
Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

MAP Kinase Signaling System

Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 42720827
DOI: 10.1007/s10555-026-10378-3
PMCID: PMC13562304

Genes

BRAF
MAP2K1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics.PMID 42720827Read ↗

Langerhans cell histiocytosis: current advances in molecular pathogenesis.Semantic proximity Read ↗

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.Semantic proximity Read ↗

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.Semantic proximity Read ↗

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.Semantic proximity Read ↗

Clinical features and treatment of Langerhans cell histiocytosis.Semantic proximity Read ↗

MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.Semantic proximity Read ↗

Langerhans cell histiocytosis.Semantic proximity Read ↗

Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.Semantic proximity Read ↗

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.Semantic proximity Read ↗

Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice.Semantic proximity Read ↗

RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.Semantic proximity Read ↗

Recent advances in the understanding of Langerhans cell histiocytosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.